Monday, 19 December 2016

MEK inhibitor/Taxane combination active in triple-negative breast cancer

A small clinical trial demonstrated encouraging clinical activity in triple-negative breast cancer (TNBC) treated with a MEK inhibitor and a taxane. The combination of cobimetinib (Cotellic) and paclitaxel led to confirmed partial responses in 6 of 16 patients and 2 additional unconfirmed partial responses. Five of the 6 confirmed responses proved to be durable, persisting for about 20 weeks. “This is the first study to evaluate the combination of cobimetinib and paclitaxel in triple-negative breast cancer,” Adam M. Brufsky, MD, PhD, associate chief of hematology oncology, and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh Medical Center, and colleagues concluded in a presentation at the 2016 San Antonio Breast Cancer Symposium. “The safety profile of combined cobimetinib and paclitaxel is manageable and consistent with the known safety profiles for each drug.

- See more here.

No comments:

Post a Comment